BiotechTube
Home/Pipeline/Recombinant Protein COVID-19 Vaccine

Recombinant Protein COVID-19 Vaccine

COVID-19 Prevention

ApprovedMarketedNCT04646590

Key Facts

Indication
COVID-19 Prevention
Phase
Approved
Status
Marketed
Company
Sinopharm

About Sinopharm

Sinopharm's mission is to safeguard national health security through its comprehensive pharmaceutical ecosystem. Its achievements include developing and deploying critical COVID-19 vaccines and maintaining China's primary drug supply chain. The company's strategy leverages its state-backed, vertically integrated structure to dominate domestic distribution while expanding its proprietary biopharmaceutical portfolio in vaccines, plasma products, and traditional Chinese medicine.

View full company profile

Therapeutic Areas

Infectious DiseasesHematologyOncology Supportive CareGeneral Medicine

Other COVID-19 Prevention Drugs

DrugCompanyPhase
Intranasal COVID VaccineVirpax PharmaceuticalsResearch
COVID-19 Vaccine TrialsDM Clinical ResearchNot Specified
SARS-CoV-2 VaccineEpygen BiotechNot Disclosed
COVAXINBharat BiotechCommercial
iNCOVACCBharat BiotechCommercial
IRT Platform (e.g., COVID-19)Biological MimeticsResearch/Pre-clinical
Replicon RNA COVID-19 VaccineBIKEN GroupPreclinical/Development
Convidecia Air® (XBB.1.5 Variant)CanSino BiologicsApproved
COVID-19 VaccineRecbio TechnologyNot specified
COMIRNATY® (BNT162b2)Fosun PharmaApproved
BBIBP-CorVSinopharmApproved
COVID-19 mRNA Vaccine (SYS6006)CSPC Innovation PharmaceuticalMarketed